It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cell–cell communication and physical interactions play a vital role in cancer initiation, homeostasis, progression, and immune response. Here, we report a system that combines live capture of different cell types, co-incubation, time-lapse imaging, and gene expression profiling of doublets using a microfluidic integrated fluidic circuit that enables measurement of physical distances between cells and the associated transcriptional profiles due to cell–cell interactions. We track the temporal variations in natural killer—triple-negative breast cancer cell distances and compare them with terminal cellular transcriptome profiles. The results show the time-bound activities of regulatory modules and allude to the existence of transcriptional memory. Our experimental and bioinformatic approaches serve as a proof of concept for interrogating live-cell interactions at doublet resolution. Together, our findings highlight the use of our approach across different cancers and cell types.
A microfluidic system combines the capture, co-incubation, time-lapse imaging, and gene expression profiling of doublets to measure the distances between cells and associated transcriptional profiles due to cell–cell interactions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Stanford University School of Medicine, Department of Surgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); A.C.Camargo Cancer Center, Circulating Tumor Cells Group, São Paulo, Brazil (GRID:grid.413320.7) (ISNI:0000 0004 0437 1183); Portuguese Oncology Institute of Porto (IPO Porto), Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Porto, Portugal (GRID:grid.435544.7); Lillebaelt Hospital, Department of Clinical Genetics, Vejle, Denmark (GRID:grid.459623.f) (ISNI:0000 0004 0587 0347)
2 Indraprastha Institute of Information Technology, Department of Computational Biology, New Delhi, India (GRID:grid.454294.a) (ISNI:0000 0004 1773 2689)
3 Stanford University School of Medicine, Department of Surgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Akoya Biosciences, Menlo Park, USA (GRID:grid.509697.4)
4 New Technologies Group, Fluidigm Corporation, South San Francisco, USA (GRID:grid.481625.c) (ISNI:0000 0004 0520 4061); Systems Integration Group, Inscripta Inc, Pleasanton, USA (GRID:grid.481625.c)
5 Stanford University School of Medicine, Department of Surgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Jawaharlal Nehru University, Cancer Biology Laboratory, School of Life Sciences, New Delhi, India (GRID:grid.10706.30) (ISNI:0000 0004 0498 924X)
6 New Technologies Group, Fluidigm Corporation, South San Francisco, USA (GRID:grid.481625.c) (ISNI:0000 0004 0520 4061); Seer Inc., Redwood City, USA (GRID:grid.481625.c)
7 Stanford University School of Medicine, Department of Surgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
8 New Technologies Group, Fluidigm Corporation, South San Francisco, USA (GRID:grid.481625.c) (ISNI:0000 0004 0520 4061)
9 New Technologies Group, Fluidigm Corporation, South San Francisco, USA (GRID:grid.481625.c) (ISNI:0000 0004 0520 4061); BioSkryb Genomics, Inc., Durham, USA (GRID:grid.481625.c)
10 A.C.Camargo Cancer Center, Circulating Tumor Cells Group, São Paulo, Brazil (GRID:grid.413320.7) (ISNI:0000 0004 0437 1183)
11 Indraprastha Institute of Information Technology, Department of Computational Biology, New Delhi, India (GRID:grid.454294.a) (ISNI:0000 0004 1773 2689); Indraprastha Institute of Information Technology, Department of Computer Science and Engineering, New Delhi, India (GRID:grid.454294.a) (ISNI:0000 0004 1773 2689); Indraprastha Institute of Information Technology, Centre for Artificial Intelligence, New Delhi, India (GRID:grid.454294.a) (ISNI:0000 0004 1773 2689); Queensland University of Technology, Institute of Health and Biomedical Innovation, Brisbane, Australia (GRID:grid.1024.7) (ISNI:0000000089150953)